InferCabulary, a Towson University Incubator-based education technology startup created to help solve illiteracy, received a $250,000 joint investment from the University System of Maryland (USM) Maryland Momentum Fund. The funding will be used to expand the team and to accelerate growth.
Some news out of this week’s RSA conference in San Francisco caught our attention back east: Iconic cybersecurity company McAfee announced plans to acquire Catonsville-based Light Point Security.
McAfee, the device-to-cloud cybersecurity company, today announced it has entered into a definitive agreement to acquire Light Point Security, LLC, an award-winning pioneer of browser isolation. Upon the close of the acquisition, the Light Point Security team will join McAfee.
Computer scientist Russell Taylor and chemical and biomolecular engineer Yannis Kevrekidis are among 87 new members and 18 international members selected this year.
A unique feature of the MII program is the introduction of university “site miners” to facilitate the application process for faculty inventors. These commercialization experts support faculty with preparing proposals and advocate for projects in the review process.
Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the
Datakwip, a building analytics software company in Frederick, Maryland, was internationally recognized in CEMEX Ventures top 50 most promising start-up companies working in construction technology.
Retired Maj. Gen. Linda L. Singh, former adjutant general of the Maryland National Guard, has joined Towson University as its first leader-in-residence, the university announced Monday.
Retired Major General Linda Singh was just appointed as interim Executive Director/Chief Executive Officer (ED/CEO) for TEDCO as of January 2020.
The company is developing phage-based therapies designed to target specific bacteria strains, as contrasted with antibiotics, which target multiple types of bacteria.
